Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

D3L-001

Alternative Names: D3L-001, D3L 001, D3L001
Latest Update: 2024-04-08
Latest Update Note: News Article

Product Description

D3L-001 is a novel HER2×CD47 bi-specific antibody (bsAb), which demonstrated potent and synergistic anti-tumor effect via HER2 guided CD47 co-blocking in both in vitro and in vivo models. D3L-001 is in IND enabling stage and will be developed as a new therapy for Her2 positive cancers. (Sourced from: https://www.d3bio.com/press-releases/d3-bio-announces-data-presentations-at-the-society-for-immunotherapy-of-cancer-2022)

Mechanisms of Action: CD47 Inhibitor,ERBB2 Inhibitor

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: D3 Bio (Wuxi) Co., Ltd
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for D3L-001

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
D3L-001-100

P1

Recruiting

Oncology Solid Tumor Unspecified

2026-03-11

23%
CTR20240207

P1

Recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title

04/08/2024

News Article

 Medicxi Announces $40m investment in D3 Bio

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions